News
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
Here's Why Editas Medicine Rose as Much as 15.9% Monday
Shares of gene editing leader Editas Medicine (NASDAQ: EDIT) rose nearly 16% Monday on heavy trading volume, most of which occurred shortly after the market opened. The number of shares traded in the
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
When GW Pharmaceuticals (NASDAQ: GWPH) announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. There were at least
BOIRON : Déclaration mensuelle des droits de vote au 31 juillet 2017
Le 8 août 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
What's Behind Pacific Biosciences of California's Stock Rally Today?
Shares of Pacific Biosciences of California (NASDAQ: PACB) are on the rise again. This is the third trading session in a row that the stock has marched upwards since announcing record revenues and a
bluebird bio Pauses During 2017 Data Blitz
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and
Why Minerva Neurosciences Inc. Fell 31.1% in July
Shares of Minerva Neurosciences (NASDAQ: NERV), a clinical-stage biotech focused on diseases of the central nervous system, fell more than 31% in July, according to data from S&P Global Market
Why Flexion Therapeutics Shares Shot 12.8% Higher in July
After the company hosted an investor's day on July 10, shares in Flexion Therapeutics (NASDAQ: FLXN) jumped 12.8% last month, according to S&P Global Market Intelligence.Flexion Therapeutics doesn't
Here's Why Myokardia Inc. Stock Shot Up Today
Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
Why Horizon Pharma plc Stock Is Rising Today
Horizon Pharma (NASDAQ: HZNP), a specialty pharma company, saw its shares rise by as much as 21% in pre-market trading today. The drugmaker's stock is rising in response to a better-than-expected
These 3 Biotechs Just Crushed Analyst Expectations
Earnings season is under way, and biotech business appears to be booming. But it takes more than just a good quarter to know if a biotech is poised for sustainable, long-term growth. With many
Why You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors. It's easy to see why; if a company dumps a bucket of new stock on the market, existing
Here's Why Mazor Robotics Ltd. Gained 20% in July
Shares of robot-assisted surgery start-up Mazor Robotics Ltd. (NASDAQ: MZOR) gained 20% in July, according to data from S&P Global Market Intelligence. The market boosted the stock in response to news